The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials.
 
Yutao Gong
No Relationships to Disclose
 
Kenneth L. Kehl
No Relationships to Disclose
 
Geoffrey R. Oxnard
Honoraria - Bio-Rad; Chugai Pharma; Guardant Health; Sysmex
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; DropWorks; Genentech/Roche; GRAIL; Ignyta; Inivata; LOXO; Novartis; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)
 
Sean Khozin
No Relationships to Disclose
 
Pallavi Shruti Mishra-Kalyani
No Relationships to Disclose
 
Gideon Michael Blumenthal
No Relationships to Disclose